A critical advance in neuroscience is the ability to intervene reversibly in a pathway-specific manner on interactions between brain regions, providing understanding of the causal role of those interactions, but also moving us towards targeted therapies for pathologies linked to neural pathways. We present data on pathway-specific DREADDs (Designer Receptor Exclusively Activated by Designer Drugs) in macaque monkeys. This approach is only now emerging for primates, and permits the targeted modulation of a specific neural pathway over a period of hours. We conducted two DREADD experiments to specifically target two frontal cortex networks putatively involved in decision making and exploratory behaviours. We studied the effects of the interventions with a spatial foraging task in the home-cage.In group 1 (n=2), we targeted the cortico-cortical pathway from midcingulate cortex (MCC) to dorsolateral prefrontal cortex (dlPFC), using a dual viral approach with AAV5-hSyn-DIO-hM3Dq-mCherry injected into MCC, and retrograde CAV2-Cre injected into dlPFC, inducing Cre-dependent expression of hM3Dq in MCC neurons projecting to dlPFC. In group 2 (n=2), we targeted noradrenergic Locus Coeruleus neurons projecting to MCC using injections of retrograde CAV2-PRS-HA-hM3D-hSyn-mCherry into MCC. The PRS promoter should limit DREADD expression to noradrenergic neurons projecting to MCC.We present detailed histological analysis of the brains, validating the pathway-specific infections, and preliminary results from resting state fMRI and [11C]DCZ PET. Importantly, the impact of the DREADDs could be observed at the behavioural level. Both groups of animals showed specific alterations of their foraging choices in the task when we activated DREADDs with deschloroclozapine (DCZ).